1. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor.
- Author
-
Perretti M, Chiang N, La M, Fierro IM, Marullo S, Getting SJ, Solito E, and Serhan CN
- Subjects
- Animals, Cell Line, Cells, Cultured, Humans, In Vitro Techniques, Mice, Molecular Sequence Data, Neutrophil Activation, Anti-Inflammatory Agents pharmacology, Aspirin pharmacology, Dexamethasone pharmacology, Lipid Metabolism, Peptides metabolism, Receptors, Cell Surface agonists, Receptors, Formyl Peptide, Receptors, Lipoxin
- Abstract
Aspirin (ASA) and dexamethasone (DEX) are widely used anti-inflammatory agents yet their mechanism(s) for blocking polymorphonuclear neutrophil (PMN) accumulation at sites of inflammation remains unclear. Here, we report that inhibition of PMN infiltration by ASA and DEX is a property shared by aspirin-triggered lipoxins (ATL) and the glucocorticoid-induced annexin 1 (ANXA1)-derived peptides that are both generated in vivo and act at the lipoxin A(4) receptor (ALXR/FPRL1) to halt PMN diapedesis. These structurally diverse ligands specifically interact directly with recombinant human ALXR demonstrated by specific radioligand binding and function as well as immunoprecipitation of PMN receptors. In addition, the combination of both ATL and ANXA1-derived peptides limited PMN infiltration and reduced production of inflammatory mediators (that is, prostaglandins and chemokines) in vivo. Together, these results indicate functional redundancies in endogenous lipid and peptide anti-inflammatory circuits that are spatially and temporally separate, where both ATL and specific ANXA1-derived peptides act in concert at ALXR to downregulate PMN recruitment to inflammatory loci.
- Published
- 2002
- Full Text
- View/download PDF